
Tecovirimat, previously effective against smallpox, is expected to combat monkeypox, and participants can choose between supportive treatment with tecovirimat or supportive treatment only. The primary endpoint is the percentage of patients with negative PCR results for skin lesions after 14 days. Secondary endpoints include mortality at 14 and 30 days, viral load, fever duration, and adverse events.
Like
Save
Share